Biotinylated Human CCR4 Nanodisc
Catalog No: CCR4-HB001
- Species
- Human
- Expression System
- HEK293
- Tag
- His
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human CCR4 Nanodisc is expressed in HEK293 cells with a His tag at the C-terminus. It contains amino acid residues Met1-Leu360 (UniProt accession: P51679).
Product Details
- Molecular Aliases
- C-C CKR-4; CC-CKR-4; CCR-4; CCR4; K5-5; CD194; CMKBR4; CKR-4; C-C CKR4; CC-CKR4; CKR4
- Protein Length
- Met1-Leu360
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 54.3 kDa.
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Supplied as 0.22 μm filtered solution in PBS, 200mM L-arginine (pH 7.4). Notice: Not recommended for flow cytometry in mammalian cells.
- State
- Liquid
- Storage Conditions
- Valid for 6 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Data Display
Immobilized Biotinylated Human CCR4 Nanodisc, His Tag at 5μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Anti-CCR4 Antibody, hFc Tag with the EC50 of 7.5ng/ml determined by ELISA. (QC Test)
Biotinylated Human CCR4 Nanodisc, His Tag captured on CM5 Chip via Streptavidin can bind Anti-CCR4 Antibody, hFc Tag with an affinity constant of 0.64 nM as determined in SPR assay (Biacore T200).
Background
CC chemokine receptor 4 (CCR4) is a chemokine receptor mainly expressed by T cells. CCR4 is important in the pathogenesis of many diseases, such as diabetes, multiple sclerosis, asthma, dermatitis, and cancer. This review briefly characterizes CCR4 and its ligands (CCL17, CCL22, and CCL2), and their contributions to immunological and neoplastic diseases.
References
- Yoshie O. CCR4 as a Therapeutic Target for Cancer Immunotherapy. Cancers (Basel). 2021 Nov 4;13(21):5542. doi: 10.3390/cancers13215542. PMID: 34771703; PMCID: PMC8583476.
- Bogacka J, Pawlik K, Ciapała K, Ciechanowska A, Mika J. CC Chemokine Receptor 4 (CCR4) as a Possible New Target for Therapy. Int J Mol Sci. 2022 Dec 9;23(24):15638. doi: 10.3390/ijms232415638. PMID: 36555280; PMCID: PMC9779674.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.